⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2369620 | 1.00 | — | — | |
| SCHEMBL14452969 | 1.00 | — | — | |
| SCHEMBL677379 | 1.00 | — | — | |
| SCHEMBL421189 | 1.00 | — | — | |
| SCHEMBL18255396 | 1.00 | — | — | |
| SCHEMBL16421365 | 1.00 | — | — | |
| SCHEMBL421076 | 1.00 | — | — | |
| SCHEMBL1360660 | 1.00 | — | — | |
| SCHEMBL20833033 | 0.97 | CA1 (0.42) | — | |
| SCHEMBL22260373 | 0.97 | CA1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1934174-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| WO-2007044515-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |